What is the best bladder cancer care for a male aged 74?

Hello,

Welcome to icliniq.com.

I can understand your concern.

Thank you for reaching out.

It is understandable that your father is feeling exhausted by repeated cystoscopies and Bacillus Calmette-Guérin (BCG) therapy. Recurrent non-muscle-invasive bladder cancer (NMIBC) is frustrating for many patients, especially seniors with other health conditions like diabetes and kidney issues. Even with appropriate BCG therapy, up to 50 to 70 percent of patients may experience recurrence, especially if the tumor was high grade, there was carcinoma in situ (CIS), or he was BCG-intolerant or underdosed due to side effects.

Your alternatives to repeated BCG or invasive surveillance include less invasive surveillance options. While cystoscopy remains the gold standard, discomfort can be minimized by using flexible cystoscopy instead of rigid cystoscopy, if applicable.

Additionally, urine-based surveillance tests such as NMP22 (nuclear protein 22), UroVysion (fluorescence in situ hybridization, or FISH), or CxBladder (a suite of non-invasive genomic tests optimized to help rule out urothelial bladder cancer) can be explored to triage when cystoscopy is needed. Although these tests are not replacements for cystoscopy, they can reduce unnecessary procedures when the risk is lower.

Alternative treatments to BCG are available if your father is BCG-unresponsive or intolerant. Intravesical chemotherapy alternatives include Gemcitabine alone or a Gemcitabine-Docetaxel combination, which, compared to BCG, are well tolerated even in older adults, have fewer side effects, and show good results for patients who cannot tolerate or have failed BCG.

For patients who fail BCG or cannot undergo major surgery, systemic immunotherapy options such as Atezolizumab or Nivolumab checkpoint inhibitors have been approved for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ in patients who decline cystectomy. These are administered intravenously every two to three weeks and can help delay or avoid bladder removal in selected cases.

Immunotherapy should be used with caution in patients with diabetes and those with autoimmune risk, but it can still be a good option if kidney function is borderline. Surgery, specifically radical cystectomy, is usually considered curative for recurrent high-risk non-muscle-invasive bladder cancer.

However, for older patients or those unfit for surgery, bladder-preserving protocols such as systemic immunotherapy or chemotherapy are often preferred. You can discuss several points with his urologist, including whether he is considered BCG-unresponsive or intolerant, if switching to Gemcitabine with or without Docetaxel instillations is appropriate, whether he is a candidate for systemic immunotherapy, if urine markers can be used to reduce the frequency of cystoscopies, and what the realistic outlook is with bladder preservation versus surgery.

Regardless, he will need to undergo a transurethral resection of bladder tumor (TURBT) procedure to remove the tumors found before commencing other intravesical options. If the intention is to proceed with bladder removal, confirmation that the new growths are indeed cancerous is necessary before such major surgery can be undertaken. Recurrence after BCG is common, and your father has valid reasons to want alternatives. Please let me know if you have any further questions or concerns. You are advocating for him incredibly well.

I hope this helps.

Feel free to reach out in case of further queries.

Thank you.